AGTC to Present at Upcoming Investor Conferences
H.C. Wainwright Global Life Sciences Conference( March 9-10, 2021)
A fireside chat with
Sue Washer, President & Chief Executive Officer, will be available to view on-demand beginning Tuesday, March 9, 2021at 7:00 a.m. ETthrough the entirety of the conference.
- 33rd Annual
ROTH Conference( March 15-17, 2021) Ms. Washerand Mark Shearman, Chief Scientific Officer, will participate in a fireside chat at 1:00 p.m. ETon Monday, March 15, 2021.
Audio webcasts of the presentation at the H.C. Wainwright and ROTH conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the Company's website following the events.
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.
Chief Financial Officer
T: (617) 843-5728
Chief Business Officer
T: (617) 413-2754
Source: Applied Genetic Technologies Corporation